Antibodies to infliximab are associated with lower infliximab levels and increased likelihood of surgery in pediatric IBD

Inflammatory Bowel Diseases

Volumn 21, Issue 2, 2015, Pages 307-314

  Zitomersky, Naamah L ^a   Atkinson, Benjamin J ^a   Fournier, Kerri ^a   Mitchell, Paul D ^a   Stern, Julia Bender ^a   Butler, Michael C ^a   Ashworth, Lori ^a   Hauenstein, Scott ^b   Heiner, Linda ^b   Chuang, Emil ^b   Singh, Sharat ^b   Bousvaros, Athos ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b Prometheus Laboratories Inc   (United States)

Author keywords

Antibodies to infliximab; Crohn's disease; Inflammatory bowel disease; Infliximab; Infliximab level; Loss of response; Ulcerative colitis

Indexed keywords

ADALIMUMAB; ANTIBODIES TO INFLIXIMAB; ANTIBODY; AZATHIOPRINE; C REACTIVE PROTEIN; CERTOLIZUMAB PEGOL; CORTICOSTEROID; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; NATALIZUMAB; TACROLIMUS; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; MONOCLONAL ANTIBODY;

ADOLESCENT; ADULT; ANTIBODY BLOOD LEVEL; ARTICLE; BLOOD SAMPLING; CHILDHOOD DISEASE; CLINICAL ASSESSMENT; COMPARATIVE STUDY; CONTROLLED STUDY; CROHN DISEASE; CROSS-SECTIONAL STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG WITHDRAWAL; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATORY BOWEL DISEASE; INTESTINE RESECTION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OUTCOME ASSESSMENT; PHENOTYPIC VARIATION; PREVALENCE; PRIORITY JOURNAL; TIME TO TREATMENT; TREATMENT DURATION; TREATMENT RESPONSE; ULCERATIVE COLITIS; YOUNG ADULT; BLOOD; CASE CONTROL STUDY; CHILD; COLITIS, ULCERATIVE; FOLLOW UP; IMMUNOLOGY; INFANT; NEWBORN; PRESCHOOL CHILD; PROGNOSIS;

ADOLESCENT; ADULT; ANTIBODIES; ANTIBODIES, MONOCLONAL; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; COLITIS, ULCERATIVE; CROHN DISEASE; CROSS-SECTIONAL STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFANT; INFANT, NEWBORN; MALE; PROGNOSIS; YOUNG ADULT;

EID: 84927741738     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000284     Document Type: Article

References (32)

1. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353: 2462-2476.
2. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: The ACCENT I randomised trial. Lancet. 2002;359: 1541-1549.
3. Sandborn WJ, Rutgeerts P, Feagan BG, et al. Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology. 2009;137:1250-1260.
4. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med. 2004;350:876-885.
5. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med. 2003; 348:601-608.
6. Hanauer SB, Wagner CL, Bala M, et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol. 2004;2:542-553.
7. Seow CH, Newman A, Irwin SP, et al. Trough serum infliximab: A predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. Gut. 2010;59:49-54.
8. Maser EA, Villela R, Silverberg MS, et al. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. Clin Gastroenterol Hepatol. 2006;4:1248-1254.
9. Ordas I, Feagan BG, Sandborn WJ. Therapeutic drug monitoring of tumor necrosis factor antagonists in inflammatory bowel disease. Clin Gastroenterol Hepatol. 2012;10:1079-1087.
10. Hyams J, Crandall W, Kugathasan S, et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology. 2007;132:863-873.
11. Vande Casteele N, Gils A, Singh S, et al. Antibody response to infliximab and its impact on pharmacokinetics can be transient. Am J Gastroenterol. 2013;108:962-971.
12. Baert F, Drobne D, Gils A, et al. Early trough levels and antibodies to infliximab predict safety and success of re-initiation of infliximab therapy. Clin Gastroenterol Hepatol. 2014;12:1474-1481.
13. Levesque BG, Greenberg GR, Zou G, et al. A prospective cohort study to determine the relationship between serum infliximab concentration and efficacy in patients with luminal Crohn's disease. Aliment Pharmacol Ther. 2014;39:1126-1135.
14. Wang SL, Ohrmund L, Hauenstein S, et al. Development and validation of a homogeneous mobility shift assay for the measurement of infliximab and antibodies-to-infliximab levels in patient serum. J Immunol Methods. 2012;382:177-188.
15. Van Assche G, Magdelaine-Beuzelin C, D'Haens G, et al. Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: A randomized trial. Gastroenterology. 2008;134:1861-1868.
16. Oussalah A, Chevaux JB, Fay R, et al. Predictors of infliximab failure after azathioprine withdrawal in Crohn's disease treated with combination therapy. Am J Gastroenterol. 2010;105:1142-1149.
17. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010;362: 1383-1395.
18. Levine A, Griffiths A, Markowitz J, et al. Pediatric modification of the Montreal classification for inflammatory bowel disease: The Paris classification. Inflamm Bowel Dis. 2011;17:1314-1321.
19. Hyams JS, Ferry GD, Mandel FS, et al. Development and validation of a pediatric Crohn's disease activity index. J Pediatr Gastroenterol Nutr. 1991;12:439-447.
20. Turner D, Otley AR, Mack D, et al. Development, validation, and evaluation of a pediatric ulcerative colitis activity index: A prospective multicenter study. Gastroenterology. 2007;133:423-432.
21. Harris PA, Taylor R, Thielke R, et al. Research electronic data capture (REDCap)-a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42:377-381.
22. Wang SL, Hauenstein S, Ohrmund L, et al. Monitoring of adalimumab and antibodies-to-adalimumab levels in patient serum by the homogeneous mobility shift assay. J Pharm Biomed Anal. 2013;78- 79:39-44.
23. Ben-Horin S, Yavzori M, Katz L, et al. The immunogenic part of infliximab is the F(ab')2, but measuring antibodies to the intact infliximab molecule is more clinically useful. Gut. 2011;60: 41-48.
24. Imaeda H, Andoh A, Fujiyama Y. Development of a new immunoassay for the accurate determination of anti-infliximab antibodies in inflammatory bowel disease. J Gastroenterol. 2012;47:136-143.
25. Pariente B, Pineton de Chambrun G, Krzysiek R, et al. Trough levels and antibodies to infliximab may not predict response to intensification of infliximab therapy in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2012;18:1199-1206.
26. Colombel JF, Feagan BG, Sandborn WJ, et al. Therapeutic drug monitoring of biologics for inflammatory bowel disease. Inflamm Bowel Dis. 2012;18:349-358.
27. Bortlik M, Duricova D, Malickova K, et al. Infliximab trough levels may predict sustained response to infliximab in patients with Crohn's disease. J Crohns Colitis. 2013;7:736-743.
28. Feagan BG, McDonald JW, Panaccione R, et al. Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn's disease. Gastroenterology. 2014;146:681 e1-e688 e1.
29. Cornillie F, Hanauer SB, Diamond RH, et al. Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: A retrospective analysis of the ACCENT I trial. Gut. 2014;63:1721-1727.
30. Vermeire S, Noman M, Van Assche G, et al. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. Gut. 2007;56:1226-1231.
31. Ben-Horin S, Mazor Y, Yanai H, et al. The decline of anti-drug antibody titres after discontinuation of anti-TNFs: implications for predicting reinduction outcome in IBD. Aliment Pharmacol Ther. 2012;35:714-722.
32. Steenholdt C, Brynskov J, Bendtzen K. Letter: persistence of anti-infliximab antibodies after discontinuation of infliximab in patients with IBD. Aliment Pharmacol Ther. 2012;36:499-500.